Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:
”Publication Alert
Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Health Science Reports | Volume 9, Issue 1
(e71702)
Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI
Published: 29 December 2025
This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.
• Read here.
Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.
Feedback and discussions are most welcome!”
Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali
Stay updated on all scientific advances with Hemostasis Today.
-
May 23, 2026, 12:52Fernanda Orsi: Honor to Be Speaking on ITP Diiferential Diagnosis at the 2026 Highlights of ASH
-
May 23, 2026, 12:46Jayagowri Karthikeyan: Grateful to Receive NBEMS President’s Gold Medal for Excellence In Immunohematology and Blood Transfusion
-
May 23, 2026, 12:40Aryabhatta Sadhu: Redefining Transfusion Medicine Across Obstetrics, Gynecology, and Fetal Medicine
-
May 23, 2026, 12:03Kiana Mohammadian: Do Anti-Inflammatory Cytokines Modulate Thrombosis?
-
May 23, 2026, 11:55Zikra Tazeen Mohammad Zakriya: Exploring the Link Between Vitamin D, Stroke, and Thrombosis
-
May 23, 2026, 11:33Alessandra Bosch: Swiss Delphi Consensus Study on Thrombophilia Testing Indications
-
May 23, 2026, 11:21Dip Ghosh: How CPDA-1 Keeps Transfusions Safe and Effective
-
May 23, 2026, 08:15Alexander Krupp: Asundexian Receives Priority Review Designation from China‘s NMPA
-
May 23, 2026, 07:59Toward a Dedicated Framework for MIg-Driven Hemostatic Disorders – JTH